Carl Zeiss Meditec Sees Decline in Q1 FY 2025/26

In the first quarter of fiscal year 2025/26, Carl Zeiss Meditec reported a revenue of €467.0 million, a 4.8% decrease from the previous year's €490.5 million. This decline was influenced by negative currency effects and strategic shifts. The EBITA dropped significantly to €8.1 million from last year's €35.2 million, reducing the EBITA margin to 1.7% from 7.2%.

Both strategic business units experienced declines; Ophthalmology revenues decreased by 5.1%, and Microsurgery fell by 3.7%. In terms of regional performance, EMEA remained stable while the Americas and APAC showed declines due to geopolitical volatility and weak investment climates.

With an uncertain outlook, Carl Zeiss Meditec has temporarily suspended its fiscal forecast and plans to update stakeholders later in the year with new organizational strategies aimed at enhancing efficiency and localization.